Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes
ConditionType 1 Diabetes Mellitus
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-65
SponsorVictor Chang Cardiac Research Institute
About this trial
This study will examine the effects of Tirzepatide (TZP), a glucagon-like peptide 1 (GLP1) - gastric inhibitory peptide (GIP) co-agonist, on metabolism in type 1 diabetes (T1D). Research participants with T1D will undergo measures of insulin sensitivity, and hormone levels post-meal, post-hypoglycemia and during the overnight period. These measures will be performed prior to, and after 6 weeks of treatment with TZP or placebo.
Eligibility criteria
Qualifiers
age 18-65 years
BMI ≥ 27 kg/m2
HbA1c ≤ 9.0%
insulin delivery using an automated insulin delivery system
Disqualifiers
TZP or GLP-1 receptor agonist in last 3 months; metformin or sodium glucose co-transporter 2 (SGLT2) inhibitor in the last 6 weeks; steroids, antipsychotics, immunosuppressants in the last 6 weeks.
Hypoglycemic unawareness or severe hypoglycemia last 6 months.
History of seizure disorder.
History of weight loss surgery.
Trial design
Treatments tested in this trial
- Tirzepatide 2.5mg weekly
- Placebo injection (normal saline)
Treatment groups
44 Participants
are divided into 2 treatment groupsLocations
1Victor Chang Cardiac Research Institute2010, SydneyNew South Wales, Australia
Sponsors and collaborators
Victor Chang Cardiac Research Institute
Lead sponsor
Source ClinicalTrials.gov